Summary
Elevance Health, Inc. (ELV) held its Annual Meeting of Shareholders on May 13, 2026, with a substantial quorum represented by over 194 million shares of common stock. The meeting's primary outcomes included the overwhelming election of directors, with all nominees securing significant support and terms extending to 2029. This demonstrates continued confidence in the leadership team guiding the company's strategic direction. Furthermore, shareholders provided advisory approval for the company's executive compensation practices, signaling alignment between executive pay and company performance. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 was also ratified, reinforcing established audit procedures. Notably, a shareholder proposal seeking an independent study on prohibiting corporate contributions to partisan 527 political groups did not receive sufficient support for approval, indicating shareholder sentiment against such an initiative at this time.
Key Highlights
- 1All director nominees were overwhelmingly elected for three-year terms expiring in 2029, indicating strong shareholder confidence in governance.
- 2Shareholders provided advisory approval for the company's executive compensation, with a significant majority voting in favor.
- 3The appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026 was ratified by a substantial margin.
- 4A quorum was established with 194,441,339 shares of common stock represented at the Annual Meeting.
- 5A shareholder proposal to study the impact of prohibiting corporate contributions to partisan 527 political groups was not approved by shareholders.
- 6Director Gail K. Boudreaux received a commanding 'For' vote count, highlighting strong support for her leadership.